2009
DOI: 10.1007/s12328-009-0112-x
|View full text |Cite
|
Sign up to set email alerts
|

Infliximab treatment for Crohn’s disease in a patient with IgA nephropathy

Abstract: We describe herein a case of IgA nephropathy in a 34-year-old woman with Crohn's disease (CD) treated with infliximab. CD first appeared at the age of 15 years. An elemental diet was started for remission maintenance. Ten years later, the patient suffered from a recto-vaginal fistula and subtotal colectomy with stoma formation was performed. At the age of 33 years, the patient was investigated for painless macroscopic hematuria and proteinuria. Renal biopsy revealed IgA nephropathy. Mizoribine was started but … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 16 publications
0
6
0
Order By: Relevance
“…Infliximab has previously been reported to both cause IgAN, as well as induce remission in patients with IgAN secondary to autoimmune conditions 9 10. Why one TNFα inhibitor caused IgAN, and another did not is unclear.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Infliximab has previously been reported to both cause IgAN, as well as induce remission in patients with IgAN secondary to autoimmune conditions 9 10. Why one TNFα inhibitor caused IgAN, and another did not is unclear.…”
Section: Discussionmentioning
confidence: 99%
“…Both these agents have been reported to cause IgAN among patients with CD and other autoimmune conditions. However, infliximab has also been documented to successfully treat a patient with IgAN secondary to CD 8–10. We describe the first case of IgAN as a complication of a TNFα inhibitor (adalimumab) that remained in remission despite the commencement of a second TNFα inhibitor (infliximab).…”
Section: Introductionmentioning
confidence: 99%
“…Crohn's disease complicated with IgA nephropathy has been reported [16][17][18][19][20][21]. In most cases, onset or aggravation of IgA nephropathy coincided with the worsening of Crohn disease.…”
Section: Discussionmentioning
confidence: 99%
“…In most cases, onset or aggravation of IgA nephropathy coincided with the worsening of Crohn disease. In several cases, the nephropathy subsided with improvement of the intestinal disease [16][17][18][19]. It is speculated that mucosal inflammation in the intestine promotes exposure of immune cells to various antigens in food or bacteria, which provokes increases of polymeric IgA, leading to the development of immune complexes that accumulate in the glomerulus [16][17][18][19].…”
Section: Discussionmentioning
confidence: 99%
“…Proinflammatory cytokines play a pivotal role in the inflammatory downstream events and might be a possible target for intervention. Beneficial effects of biologicals were reported in secondary IgA by inhibition: IL‐1 with anakinra ; I:‐6 with tocilizumab ; TNF with infliximab and adalimumab .…”
Section: Targeted Inhibition Of the Generation Formation And Depositmentioning
confidence: 99%